Developing the Cannabinoid Receptor 2 (CB2) pharmacopoeia: past, present, and future

Area of Science:

• Pharmacology
• Medicinal Chemistry
• Neuroscience

Background:

• Cannabinoid Receptor 2 (CB2) is a G protein-coupled receptor (GPCR) with significant therapeutic potential.
• Preclinical studies indicate CB2 activation is beneficial for autoimmune diseases, inflammation, pain, neurodegeneration, and osteoporosis.

Purpose of the Study:

• To review the current status of CB2 ligand development.
• To discuss advancements in optimizing physicochemical properties of CB2 ligands.
• To explore progress in molecular pharmacology and clinical evaluation of CB2-targeting compounds.

Main Methods:

• Review of existing literature on CB2 ligand development.
• Analysis of strategies to improve ligand physicochemical properties.
• Evaluation of preclinical and clinical data for CB2-targeting compounds.

Main Results:

• A wide range of cannabinoid ligands exist, aiding CB2 function understanding.
• Historically, CB2 ligands had poor physicochemical properties, limiting clinical use.
• Newer strategies have yielded ligands with improved 'drug-like' properties, some entering clinical trials.

Conclusions:

• CB2 receptor modulation holds therapeutic promise for various conditions.
• Optimizing ligand physicochemical properties is crucial for clinical translation.
• Continued research into CB2 ligand pharmacology and clinical evaluation is warranted.